-
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Jamaica, Westbury
-
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
NCT06908928 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Formative Evaluation For Improving Breast Cancer Hormone Receptor Testing in Tanzania
NCT05438511 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
NCT04641247 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Lake Success
-
A Patient Navigation Program for Addressing Disparities in Breast Cancer Care
NCT06350500 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Female
· New York: Buffalo
-
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT06997029 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Buffalo, New Hyde Park, New York
-
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT06774963 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Buffalo
-
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT06270706 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Lake Success
-
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
NCT05932862 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT06150664 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Buffalo
-
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT06253871 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT05150691 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Lake Success, New York, Shirley
-
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
NCT07102381 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Camillus, New York
-
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
NCT06568692 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Westbury
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
NCT05902988 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
NCT07743190 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Syracuse
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Albany, New York, Stony Brook
-
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
NCT06764940 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Stony Brook
-
A Post-treatment Supportive Service Program for the Transition Into Survivorship for Black Women Breast Cancer Survivors in Western New York
NCT06833255 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Buffalo
-
A Registry for People With T-cell Lymphoma
NCT05978141 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· New York: Commack, Harrison, New York, Uniondale
-
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
NCT06435429 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Long Island City, New York
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York, The Bronx
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT03424005 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
NCT07287995 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New Hyde Park
-
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT07488676 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Lake Success
-
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
NCT06678269 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Commack, Harrison, New York, Rockville Centre
-
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT06369285 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Rochester
-
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
NCT07220967 ·
Phase: Phase 4 ·
Ages: 18 Years and older ·
Sex: Female
· New York: Commack, Harrison, New York, Rockville Centre
-
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
NCT04895709 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of Blood Pressure Control During Cancer Treatment
NCT06023576 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: Female
· New York: Commack, Harrison, New York, Rockville Centre
-
A Study of Breast Cancer Risk Factors and Outcomes of People in Florida
NCT06780176 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT06778863 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951 ·
Phase: Phase 3 ·
Ages: 18 Years to 130 Years ·
Sex: All (male and female)
· New York: East Syracuse, New Hyde Park, New York, Stony Brook
-
A Study of Changes in Thinking Related to Aging and Cancer in Breast Cancer Survivors (TRAC)
NCT06334354 ·
Phase: Not specified ·
Ages: 60 Years to 80 Years ·
Sex: Female
· New York: Commack, Harrison, New York, Uniondale
-
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
NCT06736613 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Commack, Harrison, New York, Rockville Centre
-
A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer
NCT07768436 ·
Phase: Phase 2 ·
Ages: 70 Years and older ·
Sex: All (male and female)
· New York: Commack, Harrison, New York, Uniondale
-
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
NCT07205822 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Brooklyn, East Syracuse, Ithaca, Mineola
-
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
NCT05377996 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
NCT06099769 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Commack, Harrison, New York, Uniondale
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Buffalo, New York
-
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
NCT07503808 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Lake Success
-
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
NCT07287098 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: Female
· New York: Albany, New York, Rochester, Shirley
-
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York, Syracuse, Westbury, White Plains
-
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
NCT05307705 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York, Rochester
-
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of Language Interpretation Solutions for People With Breast Cancer
NCT06721065 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Commack, Harrison, New York, Rockville Centre
-
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
NCT06110793 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Commack, Harrison, New York, Uniondale
-
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Lake Success
-
A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer
NCT07225309 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of Mental Health Care in People With Cancer
NCT06037954 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 65 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
NCT06623396 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Commack, Harrison, New York, Uniondale
-
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: Male
· New York: Albany, New York, Syracuse
-
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery
NCT05130801 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: Female
· New York: New York
-
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT05877599 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
NCT06246968 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Commack, Harrison, New York, Rockville Centre
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
NCT04683679 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: Female
· New York: Commack, Harrison, New York, Uniondale
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NCT05837767 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Commack, Harrison, New York, Rockville Centre
-
A Study of Romosozumab in People With Breast Cancer and Osteoporosis
NCT07776613 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: Female
· New York: Commack, Harrison, New York, Uniondale
-
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
NCT05570253 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Commack, Harrison, New York, Uniondale
-
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Brooklyn, Mineola, New York, Nyack
-
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Mineola, New York
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Babylon, Brooklyn, New Hyde Park, New York
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
NCT07053085 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Commack, Harrison, New York, Rockville Centre
-
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Albany, Brooklyn, New York
-
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
NCT06134375 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· New York: New York
-
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
NCT07020117 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
NCT06144164 ·
Phase: Phase 3 ·
Ages: 18 Years to 75 Years ·
Sex: Female
· New York: Commack, Harrison, New York, Uniondale
-
A Study of a One-Time Counseling Session to Help Reduce Depression, Anxiety, and Distress in People With Breast Cancer
NCT07218250 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Female
· New York: Commack, Harrison, New York, Uniondale
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
NCT07361562 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Lake Success, New York
-
A Study of a Side Effects and Resource Navigation Program for People With Cancer
NCT07646847 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Commack, Harrison, New York, Rockville Centre
-
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
NCT05412225 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: Female
· New York: Commack, Harrison, New York, Uniondale
-
A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer
NCT07483307 ·
Phase: Phase 2 ·
Ages: 50 Years and older ·
Sex: Female
· New York: Commack, Harrison, New York, Uniondale
-
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
NCT05534438 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Commack, Harrison, New York, Uniondale
-
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
NCT05503797 ·
Phase: Phase 2 ·
Ages: 8 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Jamaica
-
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
NCT07100106 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: East Patchogue, The Bronx
-
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06330064 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York, Westbury, White Plains
-
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
NCT06682793 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
NCT05824975 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT04300556 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
NCT07540572 ·
Phase: Phase 1 ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female)
· New York: Lake Success
-
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
NCT07318805 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Long Island City, New York
-
A Study to Prevent and Improve Sexual Health Concerns for People With Breast Cancer
NCT05910294 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Female
· New York: Commack, Harrison, New York, Uniondale
-
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
NCT07310420 ·
Phase: Phase 1 ·
Ages: 18 Years to 55 Years ·
Sex: Female
· New York: Amsterdam, New York, The Bronx
-
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT07007559 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc
NCT05351424 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
NCT04305834 ·
Phase: Phase 2 ·
Ages: 70 Years and older ·
Sex: All (male and female)
· New York: Buffalo
-
Access to Genetic Testing in Underserved Patients With Cancer
NCT06422455 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Rochester
-
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
NCT06058377 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Brooklyn, East Hills, Glens Falls, Mineola
-
Adherence Intervention in Patients With Metastatic Breast Cancer
NCT06121453 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female)
· New York: New York
-
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
NCT07357597 ·
Phase: Phase 4 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: East Syracuse, Westbury, White Plains
-
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Glens Falls, Jamaica, The Bronx
-
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
NCT07492641 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Shirley
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York, Shirley